Modulators of trek (twik related k+ channels) channel function
WO2021080013A1
Inhibitors of trek (twik related k+ channels) channel function
WO2021043245A1
Hydantoin derivative
WO2021033729A1
Salt and crystal form of compound having agonistic activity to s1p5 receptor
WO2021025140A1
Dual-specific protein
WO2021025031A1
Biomarker for accessing efficacy of immune checkpoint inhibitor
WO2021020416A1
Bispecific antibody
WO2021010492A1
Compound having kdm5 inhibitory activity and pharmaceutical use thereof
WO2021006199A1
Treatment of hematologic cancer with pd-1/cd3 dual specificity protein
WO2020262603A1
Ep2 antagonist
WO2020250940A1
Immunosuppression agent
WO2020116636A1
Immunosuppressant
WO2020111018A1
Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy
WO2020059812A1
Novel salt of 4-(\{(4s)-1-(4-carbamimidoylbenzoyl)-4-[4-(methylsulfonyl)piperazin-1-yl]-l-prolyl\}amino)benzoic acid, and and novel crystal form of said salt
JP2020023490A
Pharmaceutical composition including compound having somatostatin receptor actuation activity
WO2020027200A1
Therapeutic agent for cartilage disease
WO2020027150A1
Benzene derivative
WO2019240246A1
Novel salts and novel crystal forms of piperidinol derivatives
EP3789040A1
Preventive and/or therapeutic agent for autoimmune disease comprising compound having btk inhibitory activity as active ingredient
